Clinical Trial: NCT05065866
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | H. Lee Moffitt Cancer Center and Research Institute |
| Information Provided By: | H. Lee Moffitt Cancer Center and Research Institute |
| Last Update Posted: | 2025-12-04 |
Study Overview
Brief Summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
Official Title
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Conditions
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
Intervention / Treatment
- Drug: BMS-986345
- Drug: Duvelisib
Other Study ID Numbers
- MCC-21096
Start Date (Actual)
2021-11-18
Primary Completion Date (Actual)
2024-01-02
Study Completion Date (Actual)
2024-04-24
Enrollment (Actual)
14
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | H. Lee Moffitt Cancer Center and Research Institute |
| Information Provided By: | H. Lee Moffitt Cancer Center and Research Institute |
| Last Update Posted: | 2025-12-04 |
Study Overview
Brief Summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
Official Title
A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Conditions
Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia
Intervention / Treatment
- Drug: BMS-986345
- Drug: Duvelisib
Other Study ID Numbers
- MCC-21096
Start Date (Actual)
2021-11-18
Primary Completion Date (Actual)
2024-01-02
Study Completion Date (Actual)
2024-04-24
Enrollment (Actual)
14
Study Type
Interventional
Phase
Phase 1